What first-line means for PTSD, and why the order matters
Search for PTSD treatment in Nashville and you will find trauma therapists, psychiatrists, VA programs, pain clinics offering nerve blocks, TMS centers, and ketamine clinics, all presented as options. They are not interchangeable. Clinical guidelines put them in a rough order based on how much evidence stands behind each one, and that order is worth knowing before you spend time, money, and hope.
The most influential U.S. guideline is the 2023 VA/DoD Clinical Practice Guideline for PTSD, summarized in Annals of Internal Medicine in 2024. It gives a strong recommendation to individual, manualized trauma-focused psychotherapy—Prolonged Exposure, Cognitive Processing Therapy, or EMDR—and recommends these therapies over medication. The American Psychological Association’s 2025 guideline also puts trauma-focused therapy first, though it ranks EMDR a step below CPT, PE, and trauma-focused CBT, a placement EMDR researchers challenged in a 2026 critique in the Journal of EMDR Practice and Research.
First-line does not mean the only option, and it does not mean everyone responds. It means this is where the evidence says most people should start. The newer treatments on this list are mostly for people who have walked that path without enough relief, or whose symptoms make it hard to begin.
If you are in crisis right now, please call or text 988. Veterans can press 1 for the Veterans Crisis Line.
Trauma-focused therapy: Prolonged Exposure, CPT, and EMDR
These three therapies share a principle. Rather than only managing symptoms around the memory, they help the brain process it so that it loses some of its grip. They differ in how they get there:
- Prolonged Exposure (PE) gradually and safely approaches the memory and the situations you have been avoiding, so fear can ease through repeated, supported contact.
- Cognitive Processing Therapy (CPT) works on the beliefs trauma leaves behind, such as self-blame or a sense that nowhere is safe, and helps you examine and revise them.
- EMDR (eye movement desensitization and reprocessing) pairs recalling the memory with bilateral stimulation, such as guided eye movements, in a structured protocol.
The evidence is real, and so are the limits. A 2022 randomized trial in JAMA Network Open (Schnurr and colleagues) compared PE and CPT in 916 veterans at 17 VA medical centers. Both produced meaningful improvement; PE was statistically better, but the difference was not clinically significant. About 56% of the PE group and 47% of the CPT group dropped out, rates the VA described as typical of real-world PTSD care.
A 2015 review of 36 randomized trials in JAMA (Steenkamp and colleagues) found that 49% to 70% of veterans receiving CPT or PE had clinically meaningful improvement, yet roughly two-thirds still met criteria for PTSD afterward. That is not a reason to skip therapy. It is a reason to know that other tools exist if therapy alone is not enough.
The VA offers PE and CPT across its system, so eligible veterans in Middle Tennessee can ask about them through the Tennessee Valley Healthcare System. Many private therapists in Nashville, Franklin, and nearby communities are trained in one or more of these approaches, and our guide to finding a therapist in Tennessee covers what to ask.
Medications: SSRIs, venlafaxine, and prazosin for nightmares
Sertraline and paroxetine are the only two medications FDA-approved for PTSD. The 2023 VA/DoD guideline recommends them, along with venlafaxine, for people who prefer medication or cannot access trauma-focused therapy. They usually take several weeks to show their full effect, can ease the depression, anxiety, and sleep problems that often travel with PTSD, and are inexpensive as generics. Side effects such as nausea, sleep changes, and sexual side effects lead some people to stop.
Prazosin shows how evidence can shift. Smaller studies suggested it reduced trauma nightmares, and it became widely prescribed. Then a 2018 trial in the New England Journal of Medicine (Raskind and colleagues) randomized 304 veterans with chronic PTSD and frequent nightmares to prazosin or placebo for 26 weeks and found no significant difference in nightmares, sleep quality, or overall symptoms. The VA/DoD guideline now suggests prazosin for PTSD nightmares specifically but suggests against it for PTSD overall. Some people still find it helpful. Any change to your medications belongs in a conversation with your prescribing provider.
Stellate ganglion block: one positive trial and open questions
A stellate ganglion block (SGB) is an injection of local anesthetic beside a cluster of sympathetic nerves in the neck, usually on the right side and guided by ultrasound or fluoroscopy. The aim is to quiet the body’s fight-or-flight signaling. It has long been used for certain pain conditions, and interest in PTSD grew through military medicine.
The best evidence is a 2020 randomized trial in JAMA Psychiatry (Rae Olmsted and colleagues). In 113 active-duty service members, two SGB treatments two weeks apart reduced CAPS-5 PTSD scores by 12.6 points at eight weeks, compared with 6.1 points after a sham procedure. The authors noted that baseline symptoms were mild to moderate and follow-up was short. An earlier 2016 trial of 42 service members in Regional Anesthesia and Pain Medicine (Hanling and colleagues) found no meaningful difference between SGB and sham.
With one positive and one negative trial, the VA/DoD guideline found insufficient evidence to recommend for or against SGB, and a larger multisite placebo-controlled trial in veterans is under way. Common side effects, such as a drooping eyelid or hoarseness, are temporary; serious complications are rare. Music City Ketamine does not perform SGB. Our article on ketamine versus SGB for PTSD compares the two in detail.
IV ketamine: promising, mixed, and not first-line
Ketamine works on a different system. It blocks NMDA receptors, which triggers a burst of glutamate signaling that is thought to promote new synaptic connections. One hypothesis is that this opens a period of greater flexibility in the brain, which we describe in the neuroplastic window. Ketamine is FDA-approved as an anesthetic; its use for PTSD is off-label.
The trials point in different directions. A 2014 crossover trial in JAMA Psychiatry (Feder and colleagues) gave 41 people with chronic PTSD a single infusion of ketamine or midazolam and found significantly greater PTSD symptom reduction with ketamine at 24 hours. A 2021 follow-up in the American Journal of Psychiatry tested six infusions over two weeks in 30 patients: 67% of the ketamine group responded, compared with 20% on midazolam, and among responders the median time to loss of response was 27.5 days.
A larger 2022 trial in Neuropsychopharmacology (Abdallah and colleagues) randomized 158 veterans and service members, whose PTSD had not responded to antidepressants, to eight infusions of placebo or one of two ketamine doses. It found no significant benefit for PTSD symptoms, although the standard dose improved depression. The VA/DoD guideline suggests against ketamine for PTSD.
Our honest reading: ketamine is not a replacement for trauma-focused therapy. It may be reasonable when first-line care has not been enough, when depression or exhaustion makes therapy hard to start, or as support for ongoing therapy, as described in ketamine and EMDR integration. Our main article on ketamine for PTSD goes deeper.
Spravato, MDMA-assisted therapy, and TMS
Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and for major depression with acute suicidal thoughts or behavior. It is not approved for PTSD. For someone with PTSD who also has treatment-resistant depression, it may be an option for the depression, often through insurance. See IV ketamine versus Spravato.
MDMA-assisted therapy is not FDA-approved. In August 2024 the FDA declined to approve it and asked for more data on durability, safety, and bias in the trials. In August 2026 the sponsor, now Resilient Pharmaceuticals, resubmitted its application without a new Phase 3 trial. It remains unavailable outside research, and the VA/DoD guideline found insufficient evidence for or against it. See ketamine versus MDMA-assisted therapy.
Transcranial magnetic stimulation (TMS) is FDA-cleared for depression and OCD, not PTSD. A 2018 trial in the Journal of Affective Disorders (Kozel and colleagues) found that among 103 combat veterans, those who received active rTMS before each CPT session had greater PTSD reductions than those receiving sham rTMS, sustained to six months. The VA/DoD guideline still rates the evidence as insufficient. Our ketamine versus TMS article compares the logistics.
PTSD treatments side by side
| Treatment | Evidence for PTSD | Speed | Typical cost | Where it fits |
|---|---|---|---|---|
| PE, CPT, EMDR | Strongest; VA/DoD strong recommendation | About 10–14 sessions, often weekly | Often insurance-covered; VA for eligible veterans | First-line for most people |
| Sertraline, paroxetine, venlafaxine | Moderate; VA/DoD strong recommendation | Several weeks | Low as generics | Alone or alongside therapy |
| Prazosin | Mixed; large 2018 trial negative | Weeks of dose adjustment | Low as a generic | Nightmares only, case by case |
| Stellate ganglion block | Limited; one positive, one negative RCT | RCT measured at 8 weeks | Often self-pay, roughly $1,000–$2,000+ | Adjunct, especially for hyperarousal |
| IV ketamine (off-label) | Limited, mixed; two positive, one negative RCT | Within 24 hours in trials; effects often fade within weeks | Usually self-pay; $475 per infusion at MCK | After first-line care, or when depression blocks therapy |
| Spravato | Not approved for PTSD | — | Often insured for approved depression uses | Co-occurring treatment-resistant depression |
| MDMA-assisted therapy | Not approved; FDA review pending | — | Research settings only | Not currently available |
| TMS | Limited; VA/DoD insufficient | Frequent sessions over weeks | Coverage usually tied to depression | Adjunct, often with co-occurring depression |
Costs are approximate, vary by provider and insurance, and change over time. Ask each provider for a current quote.
How to choose, and where Music City Ketamine fits
For most people, the sensible sequence is to start with a trauma-focused therapist, consider an SSRI or venlafaxine with a prescriber, and revisit the plan if progress stalls. The newer options make the most sense as additions when that path has not been enough, not as shortcuts around it.
Music City Ketamine is a CRNA-led clinic in Franklin that provides IV ketamine. We see people with PTSD who have tried therapy, medication, or both without enough relief, and people whose depression makes starting therapy feel out of reach. For trauma, we generally recommend having a therapist in place before infusions begin, and with your consent we coordinate with them. You do not have to tell us your trauma story; our approach is described in trauma-informed ketamine care, and ketamine for complex PTSD covers long-standing trauma.
Marla Peterson, CRNA, oversees every infusion, with anesthesia-level monitoring throughout. Many patients begin with six infusions over two to three weeks, at $475 per session, and insurance generally does not cover off-label ketamine. Some people do not respond, and if ketamine is not the right fit for you, we will say so. Our PTSD and trauma pages gather related resources, and veterans may find ketamine for veterans useful.